Oncoproteomics: current trends and future perspectives
- PMID: 17552924
- DOI: 10.1586/14789450.4.3.401
Oncoproteomics: current trends and future perspectives
Abstract
Oncoproteomics is the application of proteomics technologies in oncology. Functional proteomics is a promising technique for the rational identification of biomarkers and novel therapeutic targets for cancers. Recent progress in proteomics has opened new avenues for tumor-associated biomarker discovery. With the advent of new and improved proteomics technologies, such as the development of quantitative proteomic methods, high-resolution, -speed and -sensitivity mass spectrometry and protein arrays, as well as advanced bioinformatics for data handling and interpretation, it is now possible to discover biomarkers that can reliably and accurately predict outcomes during cancer management and treatment. However, there are several difficulties in the study of proteins/peptides that are not inherent in the study of nucleic acids. New challenges arise in large-scale proteomic profiling when dealing with complex biological mixtures. Nevertheless, oncoproteomics offers great promise for unveiling the complex molecular events of tumorigenesis, as well as those that control clinically important tumor behaviors, such as metastasis, invasion and resistance to therapy. In this review, the development and advancement of oncoproteomics technologies for cancer research in recent years are expounded.
Similar articles
-
Role of oncoproteomics in the personalized management of cancer.Expert Rev Proteomics. 2004 Jun;1(1):49-55. doi: 10.1586/14789450.1.1.49. Expert Rev Proteomics. 2004. PMID: 15966798 Review.
-
The molecular make-up of a tumour: proteomics in cancer research.Clin Sci (Lond). 2005 May;108(5):369-83. doi: 10.1042/CS20050006. Clin Sci (Lond). 2005. PMID: 15831087 Review.
-
Recent advances in clinical oncoproteomics.J BUON. 2007 Sep;12 Suppl 1:S31-8. J BUON. 2007. PMID: 17935275 Review.
-
Recent advances in oncoproteomics.Curr Opin Mol Ther. 2002 Jun;4(3):203-9. Curr Opin Mol Ther. 2002. PMID: 12139304 Review.
-
Strategies for plasma proteomic profiling of cancers.Proteomics. 2006 Oct;6(20):5662-73. doi: 10.1002/pmic.200600331. Proteomics. 2006. PMID: 16991194 Review.
Cited by
-
OncomiRs: the discovery and progress of microRNAs in cancers.Mol Cancer. 2007 Sep 25;6:60. doi: 10.1186/1476-4598-6-60. Mol Cancer. 2007. PMID: 17894887 Free PMC article. Review.
-
Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients.World J Hepatol. 2015 Jun 8;7(10):1312-24. doi: 10.4254/wjh.v7.i10.1312. World J Hepatol. 2015. PMID: 26052377 Free PMC article. Review.
-
New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.J Cancer Res Clin Oncol. 2011 Mar;137(3):513-9. doi: 10.1007/s00432-010-0899-3. Epub 2010 May 21. J Cancer Res Clin Oncol. 2011. PMID: 20490864 Free PMC article.
-
Contribution of oncoproteomics to cancer biomarker discovery.Mol Cancer. 2007 Apr 2;6:25. doi: 10.1186/1476-4598-6-25. Mol Cancer. 2007. PMID: 17407558 Free PMC article. Review.
-
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.Mol Cell Proteomics. 2012 Feb;11(2):M111.008821. doi: 10.1074/mcp.M111.008821. Epub 2011 Nov 7. Mol Cell Proteomics. 2012. PMID: 22064513 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources